PhoenixBio Co's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 39.89.
PhoenixBio Co's Days Inventory for the
six
months ended in Mar. 2026 was 318.79.
PhoenixBio Co's Days Payable for the
six
months ended in Mar. 2026 was 13.58.
Therefore, PhoenixBio Co's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 345.10.
PhoenixBio Co (TSE:6190) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
PhoenixBio Co Cash Conversion Cycle Related Terms
PhoenixBio Co Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for PhoenixBio Co's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6190 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, PhoenixBio Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhoenixBio Co Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhoenixBio Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where PhoenixBio Co's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
PhoenixBio Co's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhoenixBio Co (TSE:6190) has a Cash Conversion Cycle of 345.10 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on PhoenixBio Co and its competitors.
Is PhoenixBio Co's Cash Conversion Cycle too high?
PhoenixBio Co's current Cash Conversion Cycle is 345.10. The Biotechnology industry median Cash Conversion Cycle is 103.21. PhoenixBio Co's value of 345.10 is 234.4% above this industry median. Overall, PhoenixBio Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Cash Conversion Cycle compare to VRTX and REGN?
PhoenixBio Co's Cash Conversion Cycle of 345.10 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.21. PhoenixBio Co's value of 345.10 is 234.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.21, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhoenixBio Co's current Cash Conversion Cycle of 345.10 is 234.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on PhoenixBio Co and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhoenixBio Co's current Cash Conversion Cycle is 345.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円358.32, compared to a current price of 円338.00 — trading 5.7% below its estimated fair value. The current Cash Conversion Cycle is 345.10 and 234.4% above the Biotechnology industry median of 103.21. PhoenixBio Co's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Cash Conversion Cycle is 345.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhoenixBio Co (TSE:6190) Overvalued in 2026?
Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued.
The current stock price of 円338.00 is trading 5.7% below its estimated GF Value™ of 円358.32.
GuruFocus considers PhoenixBio Co to be Fairly Valued.
Key valuation signals for TSE:6190:
Cash Conversion Cycle: 345.10
GF Value™: 円358.32 vs. price of 円338.00 (5.7% below fair value)
Industry Position: 234.4% above the Biotechnology median
No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
55GF Score
Get the complete analysis for TSE:6190
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6190 has been successfully added to your 
